External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>DT Australia has a long track record as a manufacturer of pharmaceutical drugs, including both active pharmaceutical ingredients (API) and finished drug products at its facilities in Melbourne.</li><li>However, over the past decade it has been squeezed by cheaper overseas manufacturers.</li><li>IDT reported its first operating profit for a decade in FY21, supported by a Covid-related Sterile Readiness government contract to recommission its sterile manufacturing facilities that could be used to manufacture a commercial Covid-19 vaccine, if required.</li></ul><div><div><div id="ember2399"><div><div><div><div><div><div id="ember2813"><div><div><div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p></div></div></div></div></div></div></div></div></div></div></div></div>

DT Australia has a long track record as a manufacturer of pharmaceutical drugs, including both active pharmaceutical ingredients (API) and finished drug products at its facilities in Melbourne.However, over the past decade it has been squeezed by cheaper overseas manufacturers.IDT reported its first operating profit for a decade in FY21, supported by a Covid-related Sterile Readiness government contract to recommission its sterile manufacturing facilities that could be used to manufacture a commercial Covid-19 vaccine, if required.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

IDT Australia (IDT): Poised to Benefit from RNA and On-Shoring